Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rev. bras. anal. clin ; 53(3): 271-276, 20210930. tab, ilus
Article in Portuguese | LILACS | ID: biblio-1368637

ABSTRACT

Objetivo: Este trabalho visa discutir sobre a correta gestão de insumos em um laboratório de análises clínicas. Nesse tipo de atividade, o Sistema de Gestão da Qualidade embasa uma série de processos visando garantir a fidedignidade dos resultados, pautados em processos bem estabelecidos. A gestão de insumos e estoque é uma atividade integrada entre os diversos setores existentes na empresa, fundamental para a garantia da qualidade do exame. Dessa forma, falhas na política de qualidade podem desencadear prejuízos materiais, institucionais e humanos. Métodos: Para tanto, realizou-se análise em um laboratório clínico privado de Fortaleza, Ceará, de modo observacional, prospectivo e descritivo, desenvolvido como estudo de caso. Resultados: Verificou-se que, apesar de sistemas de gestão de estoque serem adotados, não há treinamento efetivo e documentação detalhada que norteie todos os processos do setor. Conclusão: A ausência de processos bem definidos de gestão de estoque pode ser interferente importante na correta liberação dos laudos de exames, gerando prejuízos importantes à organização e ao cliente.


Objective: This paper aims to discuss the correct management of inputs in a clinical analysis laboratory. In this type of activity, the Quality Management System is based on a series of processes aimed at guaranteeing the reliability of results, based on well-established processes. The management of inputs and stock is an integrated activity among the various sectors existing in the company, essential for ensuring the quality of the exam. Thus, failures in quality policy can trigger material, institutional and human losses. Methods: For this purpose, an analysis was carried out in a private clinical laboratory in Fortaleza, Ceará, in an observational, prospective and descriptive manner, developed as a case study. Results: It was found that, although inventory management systems are adopted, there is no effective training and detailed documentation to guide all processes in the sector. Conclusion: The absence of well-defined inventory management processes can be an important interferer in the correct release of examination reports, generating significant losses to the organization and the customer.


Subject(s)
Strategic Stockpile , Clinical Laboratory Services
2.
Washington; Organización Panamericana de la Salud; mar. 3, 2020. 8 p.
Non-conventional in English, Spanish | LILACS | ID: biblio-1096485

ABSTRACT

En diciembre de 2019 , un nuevo coronavirus (SARS-CoV-2) fue identificado como el agente etiológico de neumonía (COVID-19) en personas expuestas a un mercado de mariscos en Wuhan, China.* • Existen varias incertidumbres respecto a la historia natural de la enfermedad por el 2019-nCoV, incluyendo fuente(s), los mecanismos de transmisión, la capacidad de diseminación del virus, y la persistencia del virus en el ambiente y fómites. El 17 de febrero de 2020, el Centro para el Control y la Prevención de Enfermedades de China publicó un estudio con 72,314 casos registrados, de los cuales 44,672 (62%) fueron confirmados para SARS-CoV-2. Entre los casos confirmados, el 31,2% tenía más de 60 años y representaba 81% del total de las muertes. La tasa global de letalidad fue del 2,3%. Las comorbilidades más prevalentes fueron hipertensión, diabetes y enfermedades cardiovasculares. El espectro de la enfermedad se distribuyó en 81% de casos leves (casos de no-neumonía y neumonía leve), 14% de casos graves (disnea, frecuencia respiratoria mayor que 30/min, saturación de oxígeno en sangre menor a 93%, relación PaO2/FiO2 menor a 300, y/o infiltrados pulmonares mayor que 50% en un plazo de 24­48 horas), y 5% de pacientes en estado crítico, con insuficiencia respiratoria, shock séptico y/o disfunción o fallo multiorgánico.† • La implementación de terapias de apoyo oportunas, eficaces y seguras (oxígeno, antibióticos, hidratación y alivio de la fiebre/dolor) es la piedra angular de la terapia para los pacientes que desarrollan manifestaciones graves de COVID-19.‡ • Hasta el momento, no existe un tratamiento específico como antivirales para COVID-19. Han habido informes anecdóticos sobre el uso de estos agentes; sin embargo, su eficacia y seguridad aún no se han determinado.


• In December 2019 a novel coronavirus (SARS-CoV-2) was identified as the causative agent of pneumonia (COVID-19) among people exposed to a seafood market in Wuhan, China. • There are gaps in the knowledge about the natural history of COVID-19, including viral shedding, reservoirs and patterns of transmission. On February 17, 2020, the Chinese Center for Disease Control and Prevention published a study with 72,314 recorded cases, of which 44,672 (62%) were confirmed for COVID-19. Among the confirmed cases, 31.2% were over 60 years of age and accounted for 81% of the total deaths. The overall case-fatality rate was 2.3%. The most prevalent comorbid conditions were hypertension, diabetes, and cardiovascular disease. The spectrum of disease included 81% of mild cases (non-pneumonia and mild pneumonia cases), 14% severe (dyspnea, respiratory frequency higher than ≥) 30/min, blood oxygen saturation lesser than ≤ 93%, PaO2/FiO2 ratio lesser than ≤ 300, and/or lung infiltrates > 50% within 24­48 hours), and 5% of critically ill patients, with respiratory failure, septic shock, and/or multiple organ dysfunction or failure. • The implementation of timely, effective, and safe supportive therapies (oxygen, antibiotics, hydration & fever/pain relief) is the cornerstone of therapy for patients that develop severe manifestations of COVID-19.• At the moment, there is no specific treatment for COVID-19, such as antivirals. There have been anecdotal reports on the use of these agents; however, its efficacy and safety are yet to be determined. The medical devices listed in this document provide minimum standards and technical description and specifications of medical devices for supportive treatment of COVID-19. • These medical devices are not limited, and to be adaptable to all countries in the region irrespective of their different health care systems and socioeconomic disparities. In addition, they are recommended for: o Early supportive therapy and monitoring of severe acute respiratory illness (SARI) when COVID-19 infection is suspected; o Management of hypoxemic respiratory failure and Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients; o Management of septic shock in COVID-19 patients.


Subject(s)
Humans , Pneumonia, Viral/prevention & control , Risk Groups , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Coronavirus Infections/epidemiology , Pandemics/prevention & control , Betacoronavirus , Health Systems/organization & administration , China/epidemiology , Severe Acute Respiratory Syndrome/complications , Severe Acute Respiratory Syndrome/prevention & control , Strategic Stockpile/organization & administration
3.
Washington; Organización Panamericana de la Salud; mar. 27, 2020.
Non-conventional in English, Spanish | LILACS | ID: biblio-1096620

ABSTRACT

Este documento resulta una actualización a las recomendaciones interinas de la OPS para la gestión de casos de COVID19 en los servicios de salud*


This document updates PAHO's interim recommendations for case management of COVID-19 in health services. The list of priority medical devices in the context of COVID-19 provides technical descriptions and specifications for the management of patients with suspected and/or confirmed COVID-19 infection at different levels of health care.


Subject(s)
Humans , Pneumonia, Viral/prevention & control , Coronavirus Infections/prevention & control , Pandemics/prevention & control , Strategic Stockpile/organization & administration , Personal Protective Equipment/supply & distribution , Betacoronavirus , Public Health Systems
4.
Korean Journal of Blood Transfusion ; : 3-17, 2018.
Article in Korean | WPRIM | ID: wpr-713989

ABSTRACT

The blood supply can become disrupted in situations of increased demand during unexpected national catastrophes and when a patient needs a rare blood transfusion, which depends on the blood inventory in peacetime. Cryopreservation of blood, which can be stored up to 10 years, represents a possible solution to this problem by avoiding storage lesions. This review describes frozen red cell technologies, quality control issues related to post-thaw red blood cells, and preconditions and practical considerations for implementation of a frozen blood banking system in Korea.


Subject(s)
Humans , Blood Banks , Blood Transfusion , Cryopreservation , Erythrocytes , Korea , Quality Control , Strategic Stockpile
5.
Bull. W.H.O. (Online) ; 95(8): 594-598, 2017. tab
Article in English | AIM | ID: biblio-1259909

ABSTRACT

In some low- and middle-income countries, the national stores and public-sector health facilities contain large stocks of pharmaceuticals that are past their expiry dates. In low-income countries like Uganda, many such stockpiles are the result of donations. If not adequately monitored or regulated, expired pharmaceuticals may be repackaged and sold as counterfeits or be dumped without any thought of the potential environmental damage. The rates of pharmaceutical expiry in the supply chain need to be reduced and the disposal of expired pharmaceuticals needs to be made both timely and safe. Many low- and middle-income countries need to: (i)strengthen public systems for medicines' management, to improve inventory control and the reliability of procurement forecasts; (ii) reduce stress on central medical stores, through liberalization and reimbursement schemes; (iii) strengthen the regulation of drug donations; (iv) explore the salvage of officially expired pharmaceuticals, through re-analysis and possible shelf-life extension; (v) strengthen the enforcement of regulations on safe drug disposal; (vi) invest in an infrastructure for such disposal, perhaps based on ultra-high-temperature incinerators; and (vii) include user accountability for expired pharmaceuticals within the routine accountability regimes followed by the public health sector


Subject(s)
Developing Countries , Drug Storage/statistics & numerical data , Medical Waste Disposal/methods , Prescription Drugs/statistics & numerical data , Reproducibility of Results , Strategic Stockpile , Uganda
6.
Mundo saúde (Impr.) ; 37(1): 97-104, jan.- mar. 2013. ilus
Article in Portuguese | LILACS | ID: lil-757665

ABSTRACT

Diante da competitividade crescente, a gestão de estoques é necessária para evitar os altos custos com os produtos, diminuir o capital total investido pela empresa no estoque, além de evitar a falta de produtos para os clientes. Este trabalho visa a trazer uma abordagem teórico-prática a respeito da gestão de estoque de medicamentos, tendo como exemplo uma farmácia do Serviço de Atenção à Saúde (SAS). A metodologia aplicada consistiu em três partes. A primeira foi uma pesquisa bibliográfica para a construção do modelo teórico; a segunda foi o estudo de caso na farmácia do SAS; e a terceira etapa referiu-se a propostas de melhorias para uma gestão de estoque de qualidade dos medicamentos, com o objetivo de garantir o acesso da população a medicamentos seguros e eficazes. Na farmácia estudada, não havia uma padronização dos procedimentos realizados, desencadeando a falta de critérios técnicos, que impossibilitou a realização dos cálculos necessários para o controle de estoque de qualidade, sendo necessária a realização de uma contagem dos produtos existentes, para servir de ponto de partida do trabalho. Este trabalho indicou duas propostas de gestão de estoque: as fichas de prateleiras, que são ferramentas mais simples e a um custo acessível de serem executadas, e o programa de gerenciamento de materiais. Deve existir regulamentação dos procedimentos operacionais padrões entre estudantes e funcionários e estabelecer-se a divisão de trabalho com as devidas responsabilidades.


In an increasingly competitive market, the management of medication supplies is needed to avoid the high costs of pro-ducts, reduce the total capital invested by the company, and avoid a lack of products to clients. This study aims to bring a practical-theoretical approach regarding the management of medication supplies, having as an example a pharmacy of the Health Care Service (SAS). The methodology consisted in three parts: first a literature search was done to construct the theoretical model, then we did a case study in the SAS pharmacy and in the third stage we examined proposals for improvements in order to reach a quality management of medicine supplies for offering the population access to safe and effective medicines. At the pharmacy studied, there was not procedures standardization, causing a lack of technical crite-ria, which precluded the calculations required for quality inventory control, and this made necessary to count the existing products before beginning the study. This study proposed two proposals for inventory management: the form of shelves, which are more simple tools requiring fewer expenses to be executed, and material management program. There should be rules for standard operating procedures for both students and staff and the establishment of the division of labor with appropriate responsibilities for each.


Subject(s)
Humans , Delivery of Health Care , Pharmaceutical Preparations , Strategic Stockpile
SELECTION OF CITATIONS
SEARCH DETAIL